Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Memantine does not substantially affect brain stimulation reward: comparison with MK-801.

T M Tzschentke1, W J Schmidt

  • 1Department of Neuropharmacology, Zoological Institute, University of Tübingen, Mohlstr. 54/1, 72074, Tübingen, Germany. rincewind8@hotmail.com

Brain Research
|October 28, 1999
PubMed
Summary

Memantine did not significantly affect brain stimulation reward (BSR) at typical doses, unlike MK-801. This suggests memantine has limited rewarding effects, making it a potentially safer therapeutic option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of Full µ-Opioid Receptor Agonists is not Impaired by Concomitant Buprenorphine or Mixed Opioid Agonists/Antagonists - Preclinical and Clinical Evidence.

Drug research·2016
Same author

Effects of systemically and intrastriatally injected haloperidol and apomorphine on grooming, feeding and locomotion in the rat.

Behavioural processes·2014
Same author

Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit.

European journal of pain (London, England)·2014
Same author

Anticataleptic potencies of glutamate-antagonists.

Amino acids·2013
Same author

Synergistic interaction between the two mechanisms of action of tapentadol in analgesia.

The Journal of pharmacology and experimental therapeutics·2011
Same author

[Tapentadol: with two mechanisms of action in one molecule effective against nociceptive and neuropathic pain. Preclinical overview].

Schmerz (Berlin, Germany)·2011

Area of Science:

  • Neuroscience
  • Pharmacology
  • Behavioral Science

Background:

  • N-methyl-D-aspartate (NMDA) receptor antagonists, such as MK-801, can potentiate brain stimulation reward (BSR).
  • Memantine, another NMDA receptor antagonist, has different binding kinetics and affinity compared to MK-801.
  • Understanding memantine's effects on BSR is crucial for evaluating its therapeutic potential and side effect profile.

Purpose of the Study:

  • To investigate the effects of memantine on brain stimulation reward (BSR).
  • To compare the BSR-modulating effects of memantine with those of MK-801.
  • To determine if memantine exhibits rewarding effects at therapeutic doses.

Main Methods:

  • Administered varying doses of MK-801 (0.05–0.4 mg/kg) and memantine (1–17.5 mg/kg) to subjects.

Related Experiment Videos

  • Measured changes in threshold frequency and response rate in brain stimulation reward paradigms.
  • Analyzed dose-dependent effects and compared the efficacy of memantine versus MK-801.

    • Main Results:

    • MK-801 produced significant, dose-dependent decreases in threshold frequency, indicating potentiation of BSR.
    • Memantine demonstrated minimal effects on threshold frequencies, even at high doses.
    • Both drugs, at their highest tested doses, led to a reduction in maximum response rate.

    Conclusions:

    • Memantine did not substantially influence BSR at low to intermediate doses.
    • The findings suggest memantine is largely devoid of rewarding effects within a therapeutic dose range.
    • Memantine's limited impact on BSR contrasts with MK-801, highlighting differential NMDA receptor antagonist effects.